Content about Hypertension

March 7, 2014

A study published online Friday shows that the omega-3 fatty acids EPA and DHA — commonly found in fatty fish and fish oil supplements — are as effective, if not more effective, in lowering blood pressure as some of the commonly recommended lifestyle changes like increasing physical activity and restricting alcohol and sodium intake.

SALT LAKE CITY — A study published online Friday shows that the omega-3 fatty acids EPA and DHA — commonly found in fatty fish and fish oil supplements — are as effective, if not more effective, in lowering blood pressure as some of the commonly recommended lifestyle changes like increasing physical activity and restricting alcohol and sodium intake. The findings, released by the American Journal of Hypertension, are good news, especially for those with elevated blood pressure.

February 26, 2014

Medication to treat high blood pressure in older patients appears to be associated with an increased risk for serious injury from falling, such as a hip fracture or head injury, especially in older patients who have been injured in previous falls, the JAMA Network Journals reported Monday.

CHICAGO — Medication to treat high blood pressure in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls, the JAMA Network Journals reported Monday. 

Most people older than 70 years have high blood pressure, and blood pressure control is key to reducing risk for myocardial infarction and stroke. Previous research has suggested that blood pressure medications may increase risk of falls and fall injuries.

December 23, 2013

The Food and Drug Administration has approved a new drug made by United Therapeutics for treating pulmonary arterial hypertension, the company said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by United Therapeutics for treating pulmonary arterial hypertension, the company said Monday.

The FDA approved Orenitram (treprostinil) extended-release tablets for treating certain PAH patients to improve exercise capacity. PAH is a disease in which abnormally high blood pressure in the arteries of the lungs causes the right side of the heart to work harder than normal, according to the National Library of Medicine.

November 27, 2013

Researchers at the University of Dundee and University College London on Wednesday reported that taking the maximum daily dose of some medicines would exceed the recommended daily limits for sodium, without any additional dietary intake, and potentially become an added risk factor for heart disease.

LONDON — Researchers at the University of Dundee and University College London on Wednesday found that taking the maximum daily dose of some medicines would exceed the recommended daily limits for sodium, without any additional dietary intake and potentially become an added risk factor for heart disease.

They say the public "should be warned about the potential dangers of high sodium intake from prescribed medicines" and that sodium-containing formulations "should be prescribed with caution only if the perceived benefits outweigh the risks."

November 4, 2013

Silvergate Pharmaceuticals has launched a new drug for treating high blood pressure in children, the company said Monday.

DENVER — Silvergate Pharmaceuticals has launched a new drug for treating high blood pressure in children, the company said Monday.

The drug maker announced the availability of Epaned (enalapril maleate) powder for oral suspension, for treating hypertension in patients older than 1 month. Enalapril is one of the most commonly prescribed medicines in the United States for high blood pressure. Epaned was approved in August 2013 as a flavored liquid solution to appeal to children and others who have difficulty swallowing enalapril tablets.

October 21, 2013

The Food and Drug Administration has approved a new drug made by Actelion Pharmaceuticals for treating pulmonary arterial hypertension.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Actelion Pharmaceuticals for treating pulmonary arterial hypertension.

The agency announced the approval of Opsumit (macitentan) for adults with PAH, a chronic, progressive and debilitating disease caused by high blood pressure in the arteries that connect the heart to the lungs that can lead to death or the need for lung transplantation.

October 9, 2013

The Food and Drug Administration today approved Adempas, also known as riociguat, to treat adults with two forms of pulmonary hypertension, which is caused by abnormally high blood pressure in the arteries of the lungs.

SILVER SPRING, Md. — The Food and Drug Administration today approved Adempas, also known as riociguat, to treat adults with two forms of pulmonary hypertension, which is caused by abnormally high blood pressure in the arteries of the lungs.

July 10, 2013

A new study by researchers at the University of Washington provides further evidence that most of the health problems affecting the country are linked to lifestyle choices.

SEATTLE — A new study by researchers at the University of Washington provides further evidence that most of the health problems affecting the country are linked to lifestyle choices.

The study, by the university's Institute for Health Metrics and Evaluation, listed the top 10 risk factors for health loss in 2010 and the number of deaths attributed to each and appeared in the Journal of the American Medical Association.

July 10, 2013

Pharmacists remotely monitoring patients helped them achieve better blood-pressure control than physicians in usual care, according to a new study.

NEW YORK — Pharmacists remotely monitoring patients helped them achieve better blood-pressure control than physicians in usual care, according to a new study.

June 3, 2013

People with Type 2 diabetes or high blood pressure should be evaluated for sleep apnea, a medical group said Monday.

BALTIMORE — People with Type 2 diabetes or high blood pressure should be evaluated for sleep apnea, a medical group said Monday.

The American Academy of Sleep Medicine advised that anyone with the two conditions be evaluated at its annual conference, SLEEP 2013.

May 22, 2013

The Food and Drug Administration has approved a generic heart disease drug made by Sandoz, the company said.

PRINCETON, N.J. — The Food and Drug Administration has approved a generic heart-disease drug made by Sandoz, the company said Wednesday.

Sandoz, the generics division of Swiss drug maker Novartis, announced the approval of candesartan cilexetil tablets, a generic version of AstraZeneca's Atacand.

The drug is used to treat some types of heart failure in adults with left ventricular systolic dysfunction, as well as high blood pressure in adults and children as young as 1.

Atacand had sales of $120.3 million in 2012, according to IMS Health.

March 21, 2013

In collaboration with Walgreens, the University of Nebraska Medical Center unveiled a new treatment model to help positively impact clinical outcomes for hypertension and Type 2 diabetes patients through a program made possible by a National Association of Chain Drug Stores Foundation grant.

KEARNEY, Neb. — In collaboration with Walgreens, the University of Nebraska Medical Center on Wednesday unveiled a new treatment model to help positively impact clinical outcomes for hypertension and Type 2 diabetes patients through a program made possible by a National Association of Chain Drug Stores Foundation grant. 

March 15, 2013

PharmaSmart International’s comprehensive blood pressure program has recently been validated in two new, independent scientific studies, the company announced today. The company also announced a partnership with Rx-30 Pharmacy System that offers an automated clinical integration of validated PharmaSmart biometrics within the patient record.

ROCHESTER, N.Y. — PharmaSmart International’s comprehensive blood pressure program has recently been validated in two new, independent scientific studies, the company announced today. The company also announced a partnership with Rx-30 Pharmacy System that offers an automated clinical integration of validated PharmaSmart biometrics within the patient record.

February 15, 2013

A new study indicates that the United States could prevent up to half a million deaths during the next 10 years by reducing salt intake, according to published reports.

NEW YORK — A new study indicates that the United States could prevent up to half a million deaths during the next 10 years by reducing salt intake, according to published reports.

February 14, 2013

The Food and Drug Administration has accepted the resubmission of a regulatory approval application from United Therapeutics for a drug to treat pulmonary arterial hypertension, the drug maker said.

SILVER SPRING, Md. — The Food and Drug Administration has accepted the resubmission of a regulatory approval application from United Therapeutics for a drug to treat pulmonary arterial hypertension, the drug maker said Thursday.

The FDA originally declined to approve the drug, treprostinil diolamine extended-release tablets, in a letter submitted to the company in October 2012.

The agency plans to decide whether or not to approve the drug in March of this year, United Therapeutics said.

February 11, 2013

Bartell Drugs has introduced PharmaSmart blood pressure testing kiosks at all 58 of its stores, the regional retail pharmacy chain said Monday.

SEATTLE — Bartell Drugs has introduced PharmaSmart blood-pressure testing kiosks at all 58 of its stores, the regional retail pharmacy chain said Monday.

Bartell said it was the first drug store chain in the Pacific Northwest to provide the new kiosks, made by Rochester, N.Y.-based PharmaSmart International.

February 1, 2013

Patients who take a drug for losing weight may experience improvement in multiple cardiovascular disease risk factors, according to a new study.

MOUNTAIN VIEW, Calif. — Patients who take a drug for losing weight may experience improvement in multiple cardiovascular disease risk factors, according to a new study.

December 7, 2012

The Food and Drug Administration has approved a generic hypertension drug made by Mylan, the company said.

PITTSBURGH — The Food and Drug Administration has approved a generic hypertension drug made by Mylan, the company said.

Mylan announced the approval and launch of candesartan cilexetil and hydrochlorothiazide tablets in the 16/12.5-mg, 32/12.5-mg and 32/25-mg strengths. Mylan said it was the first company to submit a complete regulatory approval application for the drug and is thus entitled to 180 days of market exclusivity in which to compete directly with the branded version.

November 19, 2012

Dr. Reddy's Labs has launched a generic drug for treating pulmonary arterial hypertension, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating pulmonary arterial hypertension, the company said.

Dr. Reddy's announced the launch of sildenafil tablets in the 20 mg strength in 90-count bottles. The drug is a generic version of Pfizer's Revatio.

Revatio had sales of $338.67 million during the 12-month period ended in September, according to IMS Health.

November 13, 2012

The Food and Drug Administration has approved a generic drug made by Mylan for treating pulmonary arterial hypertension, the drug maker said Tuesday.

PITTSBURGH — The Food and Drug Administration has approved a generic drug made by Mylan for treating pulmonary arterial hypertension, the drug maker said Tuesday.

Mylan announced the FDA approval of sildenafil citrate tablets in the 20-mg strength, a generic version of Pfizer's Revatio. The drug is used to treat adults with PAH to improve exercise ability and delay clinical worsening of the condition.

Revatio had sales of about $339 million during the 12-month period ended in September, according to IMS Health.

November 12, 2012

The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

Watson said the FDA approved its sildenafil tablets in the 20 mg strength through a subsidiary. Watson said it would launch the drug "in the near future."

The drug is a generic version of Pfizer's Revatio tablets, which had sales of about $339 million during the 12-month period ended in September, according to IMS Health.

November 8, 2012

Members of a prescription-drug program offered by Humana to Medicare beneficiaries will soon be able to obtain hypertension drugs from Walmart for a penny.

BENTONVILLE, Ark. — Members of a prescription drug program offered by Humana to Medicare beneficiaries will soon be able to obtain hypertension drugs from Walmart for a penny.

That's right: $0.01.

October 23, 2012

The Food and Drug Administration is expected to decide at the end of this week whether to approve a new oral drug for pulmonary arterial hypertension made by United Therapeutics.

NEW YORK — The Food and Drug Administration is expected to decide at the end of this week whether to approve a new oral drug for pulmonary arterial hypertension made by United Therapeutics.

October 18, 2012

A company that makes health kiosks has joined a campaign to promote blood pressure management among patients with hypertension.

ROCHESTER, N.Y. — A company that makes health kiosks has joined a campaign to promote blood pressure management among patients with hypertension.

September 28, 2012

Generic drug maker Mylan has received regulatory approval for a drug used to treat high blood pressure, also known as hypertension, the company said Friday.

PITTSBURGH — Generic drug maker Mylan has received regulatory approval for a drug used to treat high blood pressure, also known as hypertension, the company said Friday, saying that it would launch both drugs immediately.

Mylan said the Food and Drug Administration approved its irbesartan tablets in the 75 mg, 150 mg and 300 mg strengths and irbesartan and hydrochlorothiazide tablets in the 150 mg/12.5 mg and 300 mg/12.5 mg strengths. The drugs are respectively generic versions of Sanofi's Avapro and Avalide.